Virbagen Omega
Active substance
ATC code
Species
Dogs and cats.
Indications
Dogs:
Reduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.
Cats:
Treatment of cats infected with FeLV (Feline Leukemia Virus) and/or FIV (Feline Immunodeficiency Virus), in non-terminal clinical stages, from the age of 9 weeks. In a field study conducted, it was observed that there was:
- a reduction of clinical signs during the symptomatic phase (4 months) - a reduction of mortality:
• in anaemic cats, mortality rate of about 60 % at 4, 6, 9 and 12 months was reduced by approximately 30 % following treatment with interferon.
• in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20 % following treatment with interferon. In cats infected by FIV, mortality was low (5 %) and was not influenced by the treatment.
Dose to be administered and administration route
Dogs: Intravenous use
Cats: Subcutaneous use
The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension containing 5 MU or 10 MU of recombinant interferon.
Dogs:
The reconstituted product should be injected intravenously once daily for 3 consecutive days. The dose is 2.5 MU/kg bodyweight.
Cats:
The reconstituted veterinary medicinal product should be injected subcutaneously once daily for 5 consecutive days. The dose is 1 MU/kg bodyweight. Three separate 5-day treatments must be performed at day 0, day 14 and day 60.
The veterinary medicinal product should be used with the accompanying solvent only.
Adverse reactions
Dogs:
Very common (>1 animal / 10 animals treated): | Decreased white blood cells1, Decreased platelet count1, Decreased red blood cell count1, Elevated alanine aminotransferase (ALT)1 |
Common (1 to 10 animals / 100 animals treated): | Hyperthermia2,3 Lethargy2 |
1Slight, Return to normal in the week following the last injection.
2Slight and Transient.
33-6 hours after injection.
Cats:
Very common (>1 animal / 10 animals treated): | Decreased white blood cells1, Decreased platelet count1, Decreased red blood cell count1, Elevated alanine aminotransferase (ALT)1 |
Common (1 to 10 animals / 100 animals treated): | Hyperthermia2,3 Lethargy2 Digestive tract disorders (e.g. Diarrhoea, Vomiting)2 |
1Slight, Return to normal in the week following the last injection.
2Slight and Transient.
33-6 hours after injection.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
